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Summary
Background The 13-valent pneumococcal conjugate vaccine (PCV13) protects against key serotypes that increased 
after routine immunisation with the seven-valent vaccine (PCV7), but its potential for herd protection and serotype 
replacement is uncertain. The aim of this study was to analyse the eﬀ ect of the 13-valent pneumococcal conjugate 
vaccine on invasive pneumococcal disease in England and Wales 4 years after its introduction.
Methods We used a national dataset of electronically reported and serotyped invasive pneumococcal disease cases in 
England and Wales to estimate incidence rate ratios (IRRs) for vaccine and non-vaccine type invasive pneumococcal 
disease between July, 2013, and June, 2014, versus the pre-PCV13 and pre-PCV7 baseline. Incidence rates were 
corrected for missing serotype data and changes in surveillance sensitivity over time. An over-dispersed Poisson 
model was used to estimate IRRs and conﬁ dence intervals.
Findings Incidence of invasive pneumococcal disease in the epidemiological year 2013/14 decreased by 32% compared 
with the pre-PCV13 baseline (incidence 10∙14 per 100 000 in 2008–10 vs 6∙85 per 100 000 in 2013/14; IRR 0∙68, 95% CI 
0∙64–0∙72). This was due to an 86% reduction of the serotypes covered by PCV7 (1∙46 vs 0∙20 per 100 000; 
IRR 0∙14, 0∙10–0∙18) and a 69% reduction of the additional six serotypes covered by PCV13 (4∙48 vs 1∙40 per 100 000; 
IRR 0∙31, 0∙28–0∙35). When compared with the pre-PCV7 baseline, there was a 56% overall reduction in invasive 
pneumococcal disease (15∙63 vs 6∙85 per 100 000; IRR 0∙44, 95% CI 0∙43–0∙47). Compared with the pre-PCV13 
baseline, the incidence of non-PCV13 serotypes increased (incidence all ages 4∙19 vs 5∙25 per 100 000; IRR 1∙25, 
95% CI 1∙17–1∙35) due to increases across a broad range of serotypes in children younger than 5 years and in people 
aged 45 years or more. In children younger than 5 years, incidence of non-PCV13 serotypes in 2013/14 was higher 
than in 2012/13 (age <2 years: 12∙03 vs 10∙83 per 100 000; age 2–4 years: 4∙08 vs 3∙63 per 100 000).
Interpretation 8 years of PCV use in England and Wales has reduced the overall incidence of invasive pneumococcal 
disease by more than 50%. The herd protection induced by PCV7 is continuing, and similar indirect protection is 
occurring from the additional serotypes covered by PCV13. There is, however, evidence of increasing invasive 
pneumococcal disease due to non-PCV13 serotypes, particularly in children younger than 5 years in 2014. If this 
increase continues, the maximum beneﬁ t of the PCV13 programme in children might already have been achieved.
Funding Public Health England funds national surveillance of invasive pneumococcal disease.
Copyright © Waight et al. Open Access article distributed under the terms of CC BY-NC-ND.
Introduction
Pneumococcal disease is a major cause of morbidity and 
mortality in young children, both in developed and 
developing country settings.1 Use of the seven-valent 
pneumococcal conjugate vaccine (PCV7) in developed 
country settings has substantially decreased the incidence 
of PCV7-type invasive pneumococcal disease, both in 
vaccinated children and older unvaccinated individuals,2 
because of a reduction in carriage of vaccine serotypes. 
However, reduction in vaccine-type invasive pneu mo coccal 
disease has generally been accompanied by an increase in 
invasive pneumococcal disease from non-vaccine serotypes, 
such as 19A and 7F, thus diminishing the eﬀ ect of PCV7 on 
overall invasive pneumococcal disease incidence.2–4 Before 
PCV7 introduction, invasive pneumococcal disease caused 
by these and other emerging serotypes was relatively 
uncommon and hence they were not included in PCV7, the 
composition of which matched the main serotypes causing 
invasive pneumococcal disease in North American children 
in the pre-PCV era.5 Higher valency PCV containing ten 
(PCV10) or 13 (PCV13) serotypes were developed to provide 
protection against the key additional serotypes and others 
that, although not common causes of invasive pneumococcal 
disease in North America and Europe, were prevalent in 
Africa and other high-incidence settings.6 Eﬃ  cacy of these 
additional serotypes was assumed by extrapolation of an 
aggregate immunological correlate of protection established 
for PCV7 serotypes, rather than direct evidence of eﬃ  cacy.7 
Whereas the correspondence between immunogenicity and 
protection varies between serotypes, data7 from England 
and Wales conﬁ rms the eﬃ  cacy of four of the additional six 
serotypes in PCV13; for serotype 3, signiﬁ cant protection 
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was not shown, and for serotype 5, there were insuﬃ  cient 
cases for analysis.
In the UK, PCV7 was introduced in September, 2006, 
with a catch-up for all children younger than 2 years, and 
rapidly achieved a routine coverage greater than 90%.8 
Within 4 years, vaccine-type invasive pneumococcal disease 
had decreased by 86% across all ages, but there was a 
signiﬁ cant increase in non-PCV7 disease that was largest in 
children younger than 5 years and adults aged 65 years or 
more.4 The 23-valent plain polysaccharide vaccine given to 
more than 70% of the latter group had no eﬀ ect on non-
PCV7 disease.9 PCV13 replaced PCV7 in April, 2010, and a 
high coverage for the routine 2, 4, 12 month schedule 
(two plus one) was achieved, similar to PCV7, but with no 
catch-up.8 On the basis of experience with PCV7 and 
carriage studies,10 we expected that the overall pneumococcal 
carriage rate in the nasopharynx would change little, but 
that the colonising serotypes would have less potential to 
cause invasive pneumococcal disease.
Public Health England manages the largest national 
invasive pneumococcal disease dataset in the world, with 
around 5000 annual reports of invasive pneumococcal 
disease from England and Wales, of which more than 
90% are serotyped.2 Using this national dataset, we 
assessed the eﬀ ect of the PCV13 programme on the 
serotype-speciﬁ c incidence of invasive pneumococcal 
disease in vaccinated cohorts and older unvaccinated age 
groups during the ﬁ rst 4 years of the programme. We 
also assessed the combined eﬀ ect of the PCV7 and PCV13 
programmes on the incidence of invasive pneumococcal 
disease, compared with the pre-PCV7 baseline.
Methods
Study design
Since 2010, invasive pneumococcal disease has been one 
of the infections that diagnostic microbiology laboratories 
in England and Wales are required to notify under Health 
Protection Legislation to Public Health England11 or 
Public Health Wales.12 Before 2010, reporting was 
voluntary. Reporting is done electronically, and cases 
from both England and Wales are collated in a central 
database by the Public Health England Centre for 
Infectious Disease Surveillance and Control. Isolates are 
also sent to the Public Health England Respiratory and 
Vaccine Preventable Bacteria Reference Unit for 
serotyping. Laboratories sending an electronic report for 
which no isolate has been received by the Respiratory 
and Vaccine Preventable Bacteria Reference Unit are 
contacted to request isolate referral.
A single dataset of laboratory-conﬁ rmed invasive 
pneumococcal disease cases in England and Wales has 
been created from electronic reports linked with data for 
the isolates sent for serotyping, using personal identiﬁ ers 
common to both datasets. The two datasets are reconciled 
annually by epidemiological year (July 1, to June 30). 
Multiple samples collected within 30 days of each other 
from the same individual are regarded as from the same 
episode. Cases of invasive pneumococcal disease are 
deﬁ ned as Streptococcus pneumoniae cultured from a 
normally sterile site. Diagnosis by DNA detection is done 
by a minority of laboratories and contributed between 
0∙2% and 3∙8% of the total; because this proportion varied 
between years, these cases were excluded from the analysis. 
Antimicrobial susceptibility data for penicillin and 
erythromycin were obtained from the electronic reports 
and categorised as susceptible, intermediate, or resistant. 
Data for isolates referred for serotyping are analysed every 
2 weeks and presented as cumulative numbers by age 
group and week throughout the epidemiological year.13
Public Health England has approval under PIAG Section 
60 of the Health and Social Act 2001 (which has been 
subsumed into the National Information Governance 
Board for Health and Social Care with Section 60—now 
Section 251 of the NHS Act 2006) to process conﬁ dential 
information from patients for the purposes of monitoring 
the eﬀ ect, eﬃ  cacy, and safety of vaccination programmes.
Procedure
We calculated incidence rate ratio (IRR) for invasive 
pneumococcal disease by comparing incidence in the 
epidemiological year 2013/14 with the average incidence 
in the 2 years preceding PCV13 introduction (July, 2008, 
to June, 2010) and the average of the pre-PCV7 baseline 
years (July, 2000, to June, 2006) using Poisson regression. 
As previously described,4 we corrected for missing age 
and serotype by assuming that reports with missing 
information had the same age and serotype distribution 
as reports for which these parameters were known. The 
proportion with missing serotype decreased from 50% of 
reports in 2001/02 to less than 10% of reports since 
PCV13 introduction; less than 1% of reports were missing 
age. We corrected for changes in surveillance sensitivity 
over time by increasing the incidence of invasive 
pneumococcal disease before 2009/10, according to the 
upward trend seen in age-speciﬁ c total rates of invasive 
pneumococcal disease for the pre-PCV7 period 
(2000/01–2005/06).4 We assumed that pre-PCV7 trends 
would continue to 2009/10 and that surveillance 
sensitivity was stable thereafter. For example, in children 
younger than 2 years, the reported cases of invasive 
pneumococcal disease increased by 3∙3% annually, so 
for 2005/06 (4 years before 2009/10), an inﬂ ation factor 
(1∙033⁴=1∙14) was applied to the raw numbers for that 
year. Annual population data for incidence calculations 
were obtained from the Oﬃ  ce for National Statistics.14
To assess the eﬀ ect of PCV13 and PCV7, overall 
incidence of invasive pneumococcal disease was 
calculated, then stratiﬁ ed by vaccine type and non-vaccine 
type invasive pneumococcal disease. Vaccine-type 
invasive pneumococcal disease was further stratiﬁ ed by 
the serotypes covered by PCV7 (serotypes 4, 6B, 9V, 14, 
18C, 19F, and 23F) and by the additional six serotypes in 
PCV13 (serotypes 1, 3, 5, 6A, 7F, and 19A). Age-speciﬁ c 
incidence rates in 2013/14 were then compared with the 
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average annual rates in 2008/09 and 2009/10 (pre-PCV13 
baseline) and 2000/01 to 2005/06 (pre-PCV7 baseline) 
with a Poisson model on unadjusted counts with an oﬀ set 
in the model for denominators (person-years), proportion 
of reports missing age or serotype each year, and the 
underlying trend. To account for extra-Poisson variability 
between years, the conﬁ dence intervals were inﬂ ated on 
the basis of the extra-Poisson variability seen in the 
2000–06 corrected data (a period without interventions).
For the main incidence analysis, six age groups were 
used (<2, 2–4, 5–14, 15–44, 45–64, and ≥65 years). The 
serotype-speciﬁ c IRR analyses used broader age groups 
(<5, 5–64, and ≥65 years). To examine the eﬀ ect of PCV13 
on the incidence of invasive pneumococcal disease from 
serotypes 6A and 6C, we split the data on the basis of 
results of retyping a random subset of one in four isolates 
before 2009 (when these serotypes were routinely 
distinguished) and applying the proportions that were 6A 
and 6C to isolates not re-typed. We calculated IRRs with 
6A included in the PCV7 group because of assumed 
cross-protection from the 6B component of PCV7. 
Signiﬁ cance (for testing the null hypothesis of IRR=1) 
was set at 5% for serotype-grouped analyses and at 1% for 
serotype-speciﬁ c analyses.
We used Stata version 13 for all statistical analyses.
Role of the funding source
The funder of the surveillance (Public Health England) 
had no role in study design, data analysis, data 
interpretation, or writing of the report. Information on 
the electronically reported cases of invasive pneumococcal 
disease is part of the national laboratory-based 
surveillance dataset managed by Public Health England. 
The corresponding author had full access to all the data 
in the study and had ﬁ nal responsibility for the decision 
to submit for publication.
Results
Figure 1 and table 1 show the adjusted annual incidence 
rates by age and serotype grouping. The overall incidence 
Figure 1: Corrected* invasive pneumococcal disease incidence from epidemiological year 2000/01 to 2013/14, by serotype grouping and age
PCV7=seven-valent pneumococcal conjugate vaccine. PCV13=13-valent pneumococcal conjugate vaccine. NVT=non-vaccine type. *Corrected for proportion of 
samples serotyped, missing age, and for the trend in total invasive pneumococcal disease up to 2009/10 (after which no trend correction was applied).
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of invasive pneumococcal disease across all age groups 
decreased by 32% (IRR 0∙68, 95% CI 0∙64–0∙72) in 
2013/14 compared with the pre-PCV13 baseline of 
2008–10. Incidence of PCV7-type invasive pneumococcal 
disease continued to decline in all age groups after 
PCV13 introduction (0∙14, 0∙10–0∙18). Incidence for the 
additional six serotypes in PCV13 also showed a 
signiﬁ cant overall decrease of 69% (0∙31, 0∙28–0∙35), 
with the largest reduction in children younger than 
5 years (age group <2 years: 0∙11, 0∙06–0∙22; age group 
2–4 years: 0∙09, 0∙04–0∙25). In 2013/14, 858 (21%) of 
4032 cases of invasive pneumococcal disease were 
attributed to serotypes included in PCV13 (table 1), with 
the lowest prevalence of 36 (14%) of 260 cases in children 
younger than 5 years.
In 2013/14, non-PCV13 serotypes increased signiﬁ cantly 
in children younger than 5 years and in adults 45 years or 
older, compared with the pre-PCV13 baseline (for all ages 
IRR 1∙25, 95% CI 1∙17–1∙35) across all age groups 
(table 1). For children younger than 5 years, the increase 
in non-PCV13 invasive pneumococcal disease compared 
with the pre-PCV13 baseline was most marked in 2013/14 
(2012/13: 1∙01, 0∙76–1∙36; 2013/14: 1∙41, 1∙08–1∙83). The 
increase in non-PCV13 invasive pneumococcal disease in 
children younger than 5 years in 2013/14 resulted in a 
higher overall incidence of invasive pneumococcal 
disease, compared with 2012/13 (12∙03 per 100 000 in 
2013/14 vs 10∙83 per 100 000 in 2012/13 for children 
younger than 2 years; 4∙08 per 100 000 in 2013/14 vs 3∙63 
in 2012/13 for children aged 2–4 years). Despite the 
increase in non-PCV13 invasive pneumococcal disease in 
people aged 45–64 and 65 years or more, there was a 
continuing downward trend in overall invasive 
pneumococcal disease incidence in both groups (ﬁ gure 1).
When serotype 6A was included as a PCV7 serotype, 
IRRs in 2013/14 were similar to those in table 1, although 
with generally smaller reductions for the additional 
PCV13 serotypes, especially in older age groups 
(appendix).
Compared with the pre-PCV7 baseline years July, 2000, 
to June, 2006, the overall incidence of invasive pneu-
mococcal disease in 2013/14 was reduced by 56% 
(IRR 0∙44, 95% CI 0∙43–0∙47) and the incidence of 
PCV7-type invasive pneumococcal disease decreased by 
97% (0∙03, 0∙02–0∙04; appendix). The incidence of non-
PCV13 type invasive pneumococcal disease, compared 
with the pre-PCV baseline, increased by 28% (1∙28, 
1∙20–1∙35) and was attributable to increases in incidence 
in children less than 5 years and adults 65 years or older 
(appendix).
Figure 2 and table 2 show adjusted annual serotype-
speciﬁ c incidence rates and IRR for ﬁ ve of the six 
additional serotypes in PCV13 in 2013/14 compared with 
the pre-PCV13 baseline; there were insuﬃ  cient cases of 
serotype 5 to merit analysis. Serotypes 1, 6A, 7F, and 19A 
decreased signiﬁ cantly in all age groups. For serotype 3, 
there were year-on-year ﬂ uctuations in incidence for all 
age-groups (ﬁ gure 2), although signiﬁ cant reductions in 
2013/14 compared with the baseline years were observed 
for the 5–64 year and 65 years and older age groups. No 
signiﬁ cant changes in serotype 6C incidence were 
observed in any age group.
Non-PCV13 serotypes 8, 10A, 12F, 15A, and 24F 
increased signiﬁ cantly in 2013/14, compared with the 
pre-PCV13 baseline, in people aged 5 years or more 
(table 2). There was a similarly diverse range of serotypes 
2008–10 
corrected* 
(raw) cases
2008–10 
incidence per 
100 000
2013/14 
corrected* 
(raw) cases
2013/14 
incidence per 
100 000
IRR 2013/14 relative 
to 2008–10 
(95% CI†)
Age <2 years
All 304 (297) 22·22 165 (172) 12·03 0·54 (0·42–0·69)
PCV7 22 (20) 1·58 5 (5) 0·38 0·24 (0·06–0·93)
PCV13 only 174 (158) 12·67 20 (19) 1·43 0·11 (0·06–0·22)
Non-vaccine type 109 (99) 7·97 140 (136) 10·23 1·28 (0·94–1·77)
Age 2–4 years
All 157 (149) 7·77 82 (88) 4·08 0·52 (0·37–0·74)
PCV7 16 (14) 0·78 3 (3) 0·15 0·20 (0·04–1·12)
PCV13 only 100 (90) 4·98 9 (9) 0·46 0·09 (0·04–0·25)
Non-vaccine type 41 (36) 2·02 70 (67) 3·46 1·71 (1·07–2·81)
Age 5–14 years
All 143 (134) 2·23 73 (74) 1·14 0·51 (0·35–0·74)
PCV7 26 (22) 0·40 2 (2) 0·03 0·09 (0·01–0·67)
PCV13 only 81 (70) 1·27 24 (22) 0·38 0·30 (0·16–0·57)
Non-vaccine type 36 (31) 0·56 46 (42) 0·72 1·29 (0·73–2·27)
Age 15–44 years
All 1056 (994) 4·67 566 (563) 2·50 0·54 (0·47–0·62)
PCV7 120 (97) 0·53 21 (19) 0·09 0·17 (0·09–0·35)
PCV13 only 562 (463) 2·49 156 (142) 0·69 0·28 (0·22–0·36)
Non-vaccine type 373 (308) 1·65 389 (354) 1·72 1·04 (0·86–1·26)
Age 45–64 years
All 1473 (1380) 10·59 1057 (1094) 7·60 0·72 (0·65–0·80)
PCV7 216 (176) 1·55 33 (31) 0·24 0·15 (0·09-0·27)
PCV13 only 633 (527) 4·55 230 (216) 1·65 0·36 (0·29–0·45)
Non-vaccine type 624 (520) 4·49 794 (747) 5·71 1·27 (1·11–1·46)
Age ≥65 years
All 2468 (2425) 27·58 1841 (2036) 20·58 0·75 (0·69–0·81)
PCV7 410 (356) 4·58 47 (48) 0·53 0·11 (0·08–0·18)
PCV13 only 924 (808) 10·33 333 (340) 3·72 0·36 (0·30–0·43)
Non-vaccine type 1134 (992) 12·67 1461 (1491) 16·33 1·29 (1·17–1·42)
All age groups
All 5599 (5386) 10·14 3784 (4032) 6·85 0·68 (0·64–0·72)
PCV7 809 (685) 1·46 111 (108) 0·20 0·14 (0·10–0·18)
PCV13 only 2474 (2120) 4·48 772 (750) 1·40 0·31 (0·28–0·35)
Non-vaccine type 2316 (1989) 4·19 2900 (2839) 5·25 1·25 (1·17–1·35)
IRR=incidence rate ratio. PCV=pneumococcal conjugate vaccine. PCV7=serotypes in the pneumococcal conjugate 
vaccine 7. PCV13 only=serotypes in the PCV13 vaccines but not the PCV7 vaccine. *Corrected for proportion of samples 
serotyped, missing age, denominator compared with 2009/10, and for the trend in total invasive pneumococcal 
disease up to 2009/10 (after whic h no trend correction was applied). †95% CI inﬂ ated from a Poisson interval based on 
over-dispersion of 2·1 seen from modelling 2000–06 pre-PCV7 all invasive pneumococcal disease data.
Table 1: Number of cases and incidence of invasive pneumococcal disease in epidemiological year 2013/14, 
compared with the baseline average of 2008/09 and 2009/10 (2008–10), by age and serotype grouping
See Online for appendix
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Figure 2: Corrected* invasive pneumococcal disease incidence for individual serotypes grouping from epidemiological year 2000/01 to 2013/14, by age
PCV7=seven-valent pneumococcal conjugate vaccine. PCV13=13-valent pneumococcal conjugate vaccine. *Corrected for proportion of samples serotyped, missing 
age, and for the trend in total invasive pneumococcal disease up to 2009/10 (after which no trend correction was applied).
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showing an increase in 2013/14 in children under 5 years 
compared with 2012/13, including serotypes 8, 15A, 
15B/C, 22F, 23B, and 24F (ﬁ gure 3). No increase in 
antimicrobial resistance for these serotypes was observed 
in 2013/14, compared with previous years; in children 
younger than 5 years, only four (3%) of 139 non-PCV13 
serotypes with information on penicillin susceptibility 
showed intermediate or full resistance in 2013/14, 
compared with one (1%) of 88 in 2012/13 and three (3%) 
of 115 in 2011/12. The equivalent rates for erythromycin 
were seven (6%) of 115 in 2013/14, four (6%) of 72 in 
2012/13, and six (8%) of 76 in 2011/12.
Discussion
PCVs have profound eﬀ ects on nasopharyngeal carriage 
of S pneumoniae. Whereas experience in both developed 
and developing countries shows that carriage of vaccine-
type serotypes is consistently reduced by vaccination 
with PCV,15–19 the eﬀ ect of PCV on non-vaccine type 
carriage, and therefore on non-vaccine type invasive 
pneumococcal disease, is more diﬃ  cult to predict. Our 
large national database of serotyped invasive pneu-
mococcal disease cases in England and Wales provides a 
unique opportunity to document the direct and indirect 
eﬀ ects of PCV across all age groups in a developed 
country with high vaccine coverage (panel).8 Furthermore, 
the use of a reduced two plus one vaccination schedule in 
the UK provides a demanding test of the programme’s 
ability to generate herd protection.
The reductions in vaccine-type invasive pneumococcal 
disease are consistent with the estimates of serotype-
speciﬁ c vaccine-eﬀ ectiveness derived for PCV13-
immunised children in England and Wales.7 In children, 
protection from four of the additional PCV13 serotypes 
(serotypes 1, 6A, 7F, and 19A) was direct and signiﬁ cant,7 
with evidence of herd protection for these same serotypes 
in older age groups. Despite the absence of a catch-up 
Age <5 years Age 5–64 years Age ≥65 years
2008–10 
corrected* 
(raw) cases
2013/14 
corrected* 
(raw) cases
IRR (95% CI†) 2013/14 relative 
to 2008–10
2008–10 
corrected* 
(raw) cases
2013/14 
corrected* 
(raw) cases
IRR (95% CI†) 2013/14 relative 
to 2008–10
2008–10 
corrected* 
(raw) cases
2013/14 
corrected* 
(raw) cases
IRR (95% CI†) 2013/14 relative 
to 2008–10
Additional serotypes covered by PCV13‡
1 59 (54) 5 (5) 0·09 (0·02–0·32); p<0·0001 458 (382) 77 (71) 0·17 (0·12–0·26); p<0·0001 102 (89) 13 (13) 0·13 (0·06–0·28); p<0·0001
3 26 (24) 8 (8) 0·32 (0·11–0·94) 178 (148) 73 (68) 0·41 (0·28–0·62); p<0·0001 256 (224) 143 (146) 0·56 (0·43–0·73); p<0·0001
6A 10 (9) 0 (0) 0·00 (0·00–0·38); p=0·002 53 (44) 5 (5) 0·10 (0·03–0·44); p=0·001 94 (82) 5 (5) 0·05 (0·01–0·19); p<0·0001
7F 90 (82) 8 (8) 0·09 (0·03–0·26); p<0·0001 430 (361) 160 (148) 0·37 (0·29–0·50); p<0·0001 173 (152) 75 (77) 0·44 (0·30–0·63); p<0·0001
19A 85 (77) 7 (7) 0·09 (0·03–0·25); p<0·0001 225 (191) 104 (97) 0·46 (0·35–0·68); p<0·0001 279 (246) 97 (99) 0·35 (0·25–0·47); p<0·0001
Non-PCV13 serotypes
6C 6 (5) 2 (2) 0·37 (0·04–3·38) 46 (39) 33 (31) 0·72 (0·36–1·32) 88 (78) 62 (63) 0·70 (0·45–1·06)
8 13 (12) 15 (15) 1·22 (0·48–3·13) 267 (221) 354 (329) 1·33 (1·07–1·63); p=0·009 153 (134) 220 (224) 1·43 (1·11–1·86); p=0·006
9N 3 (3) 1 (1) 0·37 (0·02–8·41) 55 (46) 63 (59) 1·15 (0·72–1·88) 60 (52) 71 (72) 1·18 (0·77–1·83)
10A 6 (5) 7 (7) 1·29 (0·32–5·31) 25 (21) 43 (40) 1·73 (0·95–3·54) 17 (15) 44 (45) 2·58 (1·31–5·02); p=0·006
11A 7 (6) 4 (4) 0·62 (0·12–3·21) 49 (41) 30 (28) 0·62 (0·30–1·12) 67 (59) 56 (57) 0·83 (0·53–1·32)
12F 7 (7) 15 (15) 2·13 (0·74–6·33) 106 (88) 157 (146) 1·48 (1·04–1·99) 49 (43) 105 (107) 2·12 (1·41–3·22); p<0·0001
15A 3 (3) 18 (17) 6·49 (1·50–26·94) 14 (12) 66 (62) 4·69 (1·92–8·26); p<0·0001 29 (26) 129 (132) 4·50 (2·78–7·09); p<0·0001
16F 2 (2) 1 (1) 0·47 (0·02–11·19) 18 (16) 21 (20) 1·17 (0.48–2.83) 39 (35) 53 (54) 1·34 (0·80–2·25)
22F 25 (23) 23 (22) 0·91 (0·44–1·91) 204 (169) 132 (123) 0·65 (0.47–0.87); p=0·005 239 (209) 186 (190) 0·78 (0·61–1·00)
24F 3 (3) 28 (27) 10·15 (2·53–40·21); p=0·001 7 (6) 71 (67) 10·77 (4·12–35·41); p<0·0001 14 (12) 84 (86) 6·15 (3·19–11·83); p<0·0001
31 0 (0) 0 (0) ·· 16 (13) 14 (13) 0·88 (0·33–2·44) 23 (20) 35 (36) 1·54 (0·80–2·96)
33F 17 (15) 20 (19) 1·17 (0·52–2·73) 63 (53) 64 (60) 1·03 (0·66–1·72) 76 (67) 74 (76) 0·98 (0·65–1·47)
35B 2 (2) 2 (2) 0·94 (0·08–10·94) 8 (7) 20 (19) 2·48 (0·98–9·41) 13 (12) 25 (26) 1·96 (0·86–4·37)
Where p values are not shown, comparisons were not signiﬁ cant. IRR=incidence rate ratio. PCV=pneumococcal conjugate vaccine. *Corrected for proportion of samples serotyped, missing age, denominator 
compared with 2009/10, and for the trend in total invasive pneumococcal disease up to 2009/10 (after which no trend correction was applied). †95% CI inﬂ ated from a Poisson interval based on over-dispersion 
of 2·1 seen from modelling of 2000–06 pre-PCV7 all invasive pneumococcal disease data. ‡Excluded serotype 5, which is an outbreak strain, with corrected numbers for each of the 14 years from 2000/01–
2013/14 of 49, 5, 7, 23, 5, 0, 16, 62, 43, 10, 4, 1, 4, 0.
 Table 2: Serotype-speciﬁ c number of cases and incidence rate ratio of invasive pneumococcal disease in epidemiological year 2013/14, compared with the average of 2008/09 and 
2009/10 (2008–10), by age
Figure 3: Number of invasive pneumococcal disease cases due to non-PCV13 serotypes in children younger 
than 5 years from July, 2012, to June, 2013, and from July, 2013, to June, 2014
Serotypes 15B and 15C were combined because they are considered to be one rapidly interconverting serotype. 
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programme for PCV13, a reduction in invasive 
pneumococcal disease from the additional serotypes in 
PCV13 in older age groups was already evident in the 
second year after PCV13 introduction (ﬁ gure 2). For 
serotype 6A, for which there was some direct cross-
protection from the 6B component of PCV7, eﬀ ectiveness 
was substantially higher with PCV13.7 Accordingly, the 
indirect protection against serotype 6A invasive 
pneumococcal disease in older age groups was 
substantially greater with PCV13. Data21 from the USA 
suggest that herd protection for 6A from PCV7 was 
substantial, which might reﬂ ect the more immunogenic 
three-dose priming schedule at 2, 4, and 6 months. In 
view of the higher antibody concentrations needed to 
protect against carriage compared with invasive 
pneumococcal disease,22 a greater eﬀ ect of PCV7 on 
serotype 6A carriage might be expected in the USA than 
the UK. 
Despite the high eﬀ ectiveness of the 6A component of 
PCV137 and a reduction of more than 80% in serotype 6A 
invasive pneumococcal disease in older unvaccinated age 
groups (table 2), no signiﬁ cant changes in serotype 6C 
incidence have been reported. Some cross-protection 
might have been expected, with reports of reduction in 
6C carriage,16 as well as induction of functional 
opsonophagocytic killing responses against serotype 6C 
by PCV13.23 The IRRs of serotype 3 show reductions in all 
age groups and are less than 1 in people aged 5 years or 
more, although the ﬂ uctuations in the pre-PCV13 
baseline complicate interpretation. Signiﬁ cant protection 
from this serotype was not shown in the recent Public 
Health England eﬀ ectiveness study,7 for which the 
estimate was 25∙8% (–69∙4% to 67∙5%). Although 
signiﬁ cant protection against serotype 3 was found in a 
US case-control study,24,25 the conﬁ dence intervals around 
the point estimate were wide, with no evidence of a 
reduction in serotype 3 disease at the population level.
The decline in invasive pneumococcal disease from 
PCV7 serotypes has continued post-PCV13, with a further 
86% decrease in incidence across all ages in 2013/14, 
compared with 2008–10, consistent with the ﬁ ndings 
from countries with more than 4 years PCV7 use.2 By 
2013/14, the overall incidence of PCV7-type invasive 
pneumococcal disease had decreased by 97% compared 
with the pre-PCV7 baseline (appendix). This near-
extinction of PCV7-associated invasive pneumococcal 
disease within 8 years of introduction of conjugate 
vaccination is in accordance with UK model predictions26 
and shows the profound eﬀ ect of PCV7 on carriage.10 
Although the eﬀ ect of PCV7 on non-bacteraemic 
pneumococcal pneumonia is diﬃ  cult to measure directly, 
its incidence has probably decreased similarly, in line 
with the reduction in PCV7 serotype carriage. Since the 
eﬀ ect on carriage17 and herd immunity of the additional 
eﬀ ective serotypes in PCV13 appears similar to that of 
the PCV7 serotypes, it is reasonable to assume that, in 
the coming years, there will be a similar near-extinction 
of PCV13-attributable disease, including non-bacteraemic 
pneumonia. As carriage of vaccine-type pneumococci 
and the disease they cause become progressively less 
common, the direct beneﬁ t of vaccinating older at-risk 
people will therefore diminish. In the UK, PCV13 
vaccination of high-risk groups was shown to be not cost-
eﬀ ective,27 despite their greatly elevated risk of disease, 
because of the progressive decline in vaccine-type disease 
in future cohorts.28
In England and Wales, early post-PCV13 carriage data17 
showed complete serotype replacement in the 
nasopharynx within 2 years of its introduction, 
predominantly with less invasive serotypes that have a 
lower propensity to cause invasive pneumococcal disease. 
Panel: Research in context
Systematic review
We searched PubMed using the terms “pneumococcal conjugate vaccine”, “impact after 
introduction”, “herd immunity”, “trends”, “serotype replacement”, “eﬀ ects after 
introduction”, and “reductions in invasive disease”. We searched for population-based 
surveillance studies that had data for all age groups and provided incidence rates for 
vaccine-type and non-vaccine-type invasive pneumococcal disease for at least 3 years 
after the introduction of 13-valent pneumococcal conjugate vaccine (PCV13). Most 
papers had less than 3 years of post-PCV13 incidence data, but among these papers there 
was consistent evidence of a reduction in invasive pneumococcal disease from the 
additional serotypes covered by PCV13 in the paediatric cohorts targeted for 
immunisation, with an overall reduction in invasive pneumococcal disease in children. 
Most studies also showed early evidence of reduction in PCV13-type invasive 
pneumococcal disease in older age groups. The eﬀ ect of PCV13 on non-PCV13 invasive 
pneumococcal disease was less consistent, but the duration of follow-up and power of the 
dataset to detect changes were generally restricted. No papers reported data after the 
third year of PCV13 use.
Interpretation
Our analysis of a large national surveillance dataset shows that the introduction of PCV13 
has resulted in an overall reduction in invasive pneumococcal disease in a developed 
country setting compared with the period before PCV use and compared with the 
reduction achieved by PCV7. However, as with PCV7,2 our study shows that the overall 
eﬀ ect is now being attenuated by the increase in non-PCV13 invasive pneumococcal 
disease, both in adults aged 65 years and older and in children younger than 5 years—the 
two groups with the highest incidence of pneumococcal-attributable disease. The 
increase in non-PCV13 invasive pneumococcal disease involved a broad range of 
serotypes suggesting that the next generation of higher valency vaccines with a narrow 
additional serotype coverage might have limited public health beneﬁ t. Conﬁ rmation of 
our experience in other settings with mature PCV13 programmes and in countries that 
use PCV10 will add impetus to the development of universal pneumococcal vaccines, such 
as those based on identiﬁ cation of conserved protective protein antigens. Few data for 
herd immunity and non-vaccine-type disease exist in countries using PCV10, where the 
potential for serotype replacement might be less because of the very low carriage 
prevalence of serotypes 1 and 7F (two of the additional three serotypes covered by PCV10 
compared with PCV7).10 The eﬀ ect of PCV10 and PCV13 vaccines in resource-poor 
settings, where the burden of disease, serotype distribution, and force of infection diﬀ er 
from those in Europe and North America,20 is as yet unclear. Comparative popul ation-
based, serotype-speciﬁ c surveillance data of invasive pneumococcal disease in diﬀ erent 
epidemiological settings for countries using PCV13 and PCV10 are needed to properly 
understand the eﬀ ect of PCV with restricted serotype coverage.
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The increase in non-vaccine-type invasive pneumococcal 
disease from a wide range of serotypes in the fourth year 
after PCV13 introduction in children younger than 
5 years was not associated with a change in antibiotic 
resistance, and some of the replacing serotypes (ﬁ gure 3) 
were thought to have a low invasive potential.17 Sudden 
annual increases in non-PCV13 invasive pneumococcal 
disease have occurred in children younger than 5 years 
in the past, but has returned to baseline in the subsequent 
year (ﬁ gure 1). However, provisional data13 for 2014/15 
show that the increase in non-PCV13 type invasive 
pneumococcal disease has continued. These non-
vaccine-type isolates are now being sequenced to 
investigate whether the 2014/15 increase is associated 
with the emergence of new clones, and a further carriage 
study is planned to understand current transmission 
dynamics of non-vaccine-type serotypes in young 
children who, as shown by the rapidity of the herd 
protection eﬀ ects in older age groups, are key trans-
mitters of infection in the population. The steady 
serotype replacement in invasive pneumococcal disease 
in older age groups is less surprising because both 
increasing age and the presence of comorbidities 
increase the risk of invasive pneumococcal disease by 
serotypes with low case to carrier ratios.29
Our study has a number of strengths. The dataset is 
based on national reporting, not sentinel reporting, and 
since blood cultures are rarely done outside a hospital 
setting in the UK, the clinical criteria for diagnostic 
investigation of suspected cases of invasive pneumococcal 
disease should be relatively stable with time. 
Furthermore, our incidence rates are not based solely on 
reference laboratory data, which might be aﬀ ected by the 
propensity of primary diagnostic laboratories to refer 
isolates for serotyping and vagaries of isolate viability. 
Since our surveillance spans several decades, we can 
adjust for trends in surveillance sensitivity over time and 
take into account natural secular changes in individual 
serotypes. For baseline incidence of invasive 
pneumococcal disease, we averaged data for 2008/09 and 
2009/10 because there was a relatively large increase in 
non-PCV13 invasive pneumococcal disease in children 
younger than 5 years in 2008/9 (ﬁ gure 1), which returned 
to the 2007/08 rate in 2009/10. For the additional 
serotypes in PCV13, because the replacement induced by 
PCV7 continued in unvaccinated age groups for a further 
year after PCV13 introduction, this upward trend should 
arguably be projected to infer what the incidence might 
have been in post-PCV13 years, had the vaccine not been 
introduced. Whereas this counterfactual approach has 
been used for the analysis of post PCV-13 eﬀ ect data from 
the sentinel Active Bacterial Core surveillance system in 
the USA,24 we chose not to make this assumption. Our 
herd protection estimates for the additional PCV13 
serotypes are, therefore, likely to be conservative. 
Although we do not audit completeness of reports by 
laboratories, there is a statutory requirement for all 
diagnostic laboratories to report laboratory-conﬁ rmed, 
clinically signiﬁ cant infections to Public Health 
England,11,12 and laboratories now have automated 
procedures to extract and report such cases to meet 
statutory requirements. Since statutory reporting has 
been in place since 2010, we decided not to extrapolate 
the upward trends30 in reporting of all invasive pneu-
mococcal disease on the assumption that surveillance 
sensitivity plateaued in 2010.
In conclusion, our study provides robust evidence of 
herd protection from the additional serotypes in PCV13. 
Although there is evidence of replacement disease, overall 
invasive pneumococcal disease has been reduced by 56%, 
compared with the pre-PCV7 baseline. However, the 
increase in non-PCV13 serotypes in children younger than 
5 years in 2013/14 caused a higher incidence of invasive 
pneumococcal disease than in 2012/13, sug gesting that, if 
this increase continues, the maximum population beneﬁ t 
in this age group (in which only 14% of remaining invasive 
pneumococcal disease in 2013/14 was potentially 
preventable by PCV13) might already have been achieved. 
The increase in non-PCV13 invasive pneumococcal disease 
in children and older adults involved a broad range of 
serotypes, suggesting that the 15-valent vaccine containing 
two additional serotypes, 22F and 33F,31 which in 2013/14 
included only 17% of the total non-PCV13 serotypes, might 
be insuﬃ  cient to cover the emerging non-vaccine type 
invasive pneumococcal disease.
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